Chronic Inflammatory Hypothesis in the Metabolic Syndrome

The Metabolic Syndrome at the Beginning of the XXI Century: A Genetic and Molecular Approach

Volumn , Issue , 2005, Pages 217-231

  Fernández Real, José Manuel ^a   Ricart, Wifredo ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84941283287     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-84-8174-892-5.50013-9     Document Type: Chapter

References (121)

1. Beutler B Innate immunity: an overview. Mol Immunol 2004, 40:845-859.
2. Janeway CA, Medzhitov R Innate immune recognition. Ann Rev Immunol 2002, 20:197-216.
3. Munford RS Statins and the acute phase response. N Engl J Med 2001, 344:2016-2018.
4. Pickup JC, Crook MA Is type II diabetes a disease of the innate immune system?. Diabetologia 1998, 41:1241-1248.
5. Fernández-Real JM, Ricart W Insulin resistance and inflammation in an evolutionary perspective. The contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999, 42:1367-1374.
6. Svenson KL, Pollare T, Lithell H, Hallgren R Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988, 37:125-130.
7. Svenson KL, Lundqvist G, Wide L, Hallgren R Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 1987, 36:940-943.
8. Juhan-Vague I, Thompson SG, Jespersen J Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993, 13:1865-1873.
9. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
10. Fernández-Real JM, Ricart W Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003, 24:278-301.
11. Dzielak DJ The immune system and hypertension. Hypertension 1992, 19(Suppl 1):I-36-I-44.
12. Fu MLX Do immune system changes have a role in hypertension?. J Hypertension 1995, 13:1259-1265.
13. Ebringer A, Doyle AE Raised serum IgG levels in hypertension. Br Med J 1970, 2:146-148.
14. Olsen F, Hilden M, Ibsen H Raised levels of immunoglobulins in serum of hypertensive patients. Acta Pathol Microbiol Scand 1973, 81:775-778.
15. Kristensen BO Increased serum levels of immunoglobulins in untreated and treated essential hypertension. Acta Med Scand 1978, 203:49-54.
16. Kahaleh MB, Fan PS Effect of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheumatol 1997, 15:163-167.
17. Brasier AR, Li J, Wimbish KA Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension 1996, 27:1009-1017.
18. Pausova Z, Deslauriers B, Gaudet D, Tremblay J, Kotchen TA, Larochelle P, et al. Role of tumor necrosis factor-sα gene locus in obesity and obesity-associated hypertension in French Canadians. Hypertension 2000, 36:14-19.
19. Zinman B, Hanley AJG, Harris SB, Kwan J, Fantus IG Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999, 84:272-278.
20. Dörffel Y, Lätsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmester GR, Scholze J Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999, 34:113-117.
21. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992, 175:323-329.
22. Aderka D, Engelmann H, Shemer-Avni Y, Hornik V, Galil A, Sarov B, Wallach D Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 1992, 11:157-159.
23. Aderka D, Sorkine P, Abu-Abid S, Lev D, Setton A, Cope AP, et al. Shedding kinetics of soluble Tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest 1998, 101:650-659.
24. Fernández-Real JM, Laínez B, Vendrell J, Rigla M, Castro A, Peñarroja G, et al. Shedding of Tumor Necrosis Factor-alpha Receptors, blood pressure and insulin sensitivity in type 2 diabetes mellitus. Am J Physiol-Endocrinol Metab 2002, 282:E952-E959.
25. Fernández-Real JM, Vayreda M, Richart C, Gutiérrez C, Broch M, Vendrell J, Ricart W Circulating interleukin 6 levels, blood pressure and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001, 86:1154-1159.
26. Straub RH, Hense HW, Andus J, Schölmerich J, Riegger AJ, Schunkert H Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 2000, 85:1340-1344.
27. Chae CU, Lee RT, Rifai N, Ridker PM Blood pressure and inflammation in apparently healthy men. Hypertension 2001, 38:399-403.
28. Pola R, Flex A, Gaetani E, Pola P, Bernabei R The -174 G/C polymorphism of the interleukin-6 gene promoter and essential hypertension in an elderly Italian population. J Hum Hypertens 2002, 16:637-640.
29. Fantuzzi G, Faggioni R Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000, 68:437-446.
30. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000, 105:1243-1252.
31. Havel RJ Lipid transport function of lipoproteins in blood plasma. Am J Physiol 1987, 253:E1-E5.
32. Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000, 181(Suppl 3):S462-S472.
33. Esteve E, Ricart W, Fernández-Real JM Dyslipidemia inflammation: an evolutionary conserved mechanism. Clin Nutr 2005, 24:16-31.
34. Forette B, Tortrat D, Wolmark Y Cholesterol as a risk factor for mortality in elderly women. Lancet 1989, i:868-870.
35. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on low blood cholesterol: mortality associations. Circulation 1992, 86:1046-1060.
36. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, David Curb J Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001, 358:351-355.
37. Fernández-Real JM, Gutiérrez C, Ricart W, Castiñeira MJ, Vendrell J, Richart C Plasma levels of the soluble fraction of tumor necrosis factor-α receptors 1 and 2 are independent determinants of total and LDL-Cholesterol concentrations in healthy subjects. Atherosclerosis 1999, 146:321-327.
38. Benjafield AV, Wang XL, Morris BJ Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease. J Mol Med 2001, 79:109-115.
39. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002, 23:376-383.
40. Jovinge S, Hamsten A, Tornvall P, Proudler A, Bavenholm P, Ericsson CG, et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998, 47:113-118.
41. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow R.O, Jablons D Interleukin-6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin-6 in cancer cachexia. Cancer Res 1992, 52:4113-4116.
42. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995, 136:2143-2149.
43. Fernández-Real JM, Broch M, Vendrell J, Richart C, Ricart W Interleukin 6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000, 85:1334-1339.
44. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999, 38:202-206.
45. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM Differential regulation of the p80 Tumor Necrosis Factor Receptor in human obesity and insulin resistance. Diabetes 1997, 46:451-455.
46. Fernández-Real JM, Broch M, Ricart W, Gutiérrez C, Casamitjana R, Vendrell J, Richart C Plasma Levels of the Soluble Fraction of Tumor Necrosis Factor Receptor 2 and Insulin Resistance. Diabetes 1998, 47:1757-1762.
47. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
48. Orban Z, Remaley A, Sampson M, Trajanoski Z., Chrousos GP The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 1999, 84:2126-2133.
49. Fried SK, Bunkin DA, Greenberg AS Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83:847-850.
50. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002, 8:75-79.
51. Hotamisligil GS, Shargill NS, Spiegelman BM Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
52. Fernández-Real JM, Gutiérrez C, Ricart W, Casamitjana R, Vendrell J, Fernández-Castañer M, et al. The TNF-α Nco I polymorphism influences the relationship among insulin resistance, percent body fat and increased serum leptin levels. Diabetes 1997, 46:1468-1472.
53. Skoog T, Eriksson P, Hoffstedt J, Rydén M, Hamsten A, Arner P Tumour necrosis factor-((TNF-α) polymorphisms -857C/A and -863C/A are associated with TNF-α secretion from human adipose tissue. Diabetologia 2001, 44:654-655.
54. Schreyer SA, Chua SC, LeBoeuf RC Obesity and diabetes in TNF-alpha receptor-deficient mice. J Clin Invest 1998, 102:402-411.
55. Fernández-Real JM, Vendrell J, Ricart W, Broch M, Gutiérrez C, Casamitjana R, et al. A Polymorphism of the tumor necrosis factor receptor-2 gene is associated with obesity, leptin levels and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care 2000, 23:831-837.
56. Fernández-Real JM, Broch M, Vendrell J, Gutiérrez C, Casamitjana R, Pugeat M, Richart C, Ricart W Interleukin 6 and insulin sensitivity. Diabetes 2000, 49:517-520.
57. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001, 9:414-417.
58. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
59. van Exel E, Gussekloo J, de Craen AJ, Frolich M, Bootsma-Van Der Wiel A, Westendorp RG Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002, 51:1088-1092.
60. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998, 70:281-312.
61. Stephens JM, Butts MD, Pekala PH Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumour necrosis factor-. J Mol Endocrinol 1992, 9:61-72.
62. Heinrich PC, Castell JV, Andus T Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636.
63. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002, 106:24-30.
64. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G, Giugliano D Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 2002, 87:3864-3866.
65. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.
66. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millan JL Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004, 89:806-811.
67. Castrillo A, Joseph SB, Vaidya SA, et al. Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003, 12:805-816.
68. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108.
69. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002, 186:1522-1525.
70. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002, 347:185-192.
71. Boekholdt SM, Agema WR, Peters RJ, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003, 107:2416-2421.
72. Illig T, Bongardt F, Schopfer A, et al. The endotoxin receptor TLR4 polymorphism is not associated with diabetes or components of the metabolic syndrome. Diabetes 2003, 52:2861-2864.
73. Unkelbach K, Gardemann A, Kostrzewa M, Philipp M, Tillmanns H, Haberbosch W A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999, 19:932-938.
74. Hubacek JA, Rothe G, Pit'ha J, et al. C (-260)- T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999, 99:3218-3220.
75. Ito D, Murata M, Tanahashi N, et al. Polymorphism in the promoter of lipopolysaccharide receptor CD14 and ischemic cerebrovascular disease. Stroke 2000, 31:2661-2664.
76. Shimada K, Watanabe Y, Mokuno H, Iwama Y, Daida H, Yamaguchi H Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. Am J Cardiol 2000, 86:682-684.
77. Risley P, Jerrard-Dunne P, Sitzer M, Buehler A, von Kegler S, Markus HS Carotid Atherosclerosis Progression Study. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2003, 34:600-604.
78. Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W Bacterial endotoxin is an active component of cigarette smoke. Chest 1999, 115:829-835.
79. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck study. J Am Coll Cardiol 1999, 34:1975-1981.
80. Wiedermann CJ, Kiechl S, Schratzberger P, Dunzendorfer S, Weiss G, Willeit J The role of immune activation in endotoxin-induced atherogenesis. J Endotoxin Res 2001, 7:322-326.
81. Osmand AP, Friedenson B, Gewurz H, Painter RH, Hofmann T, Shelton E Characterisation of C-reactive protein and the complement subcomponent Clt as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci USA 1977, 74:739-743.
82. Robey FA, Liu T-Y Limulin: a C-reactive protein from Limulus polyphemus. J Biol Chem 1981, 256:969-975.
83. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731-733.
84. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
85. McMillan DE Increased levels of acute-phase proteins in diabetes. Metabolism 1989, 38:1042-1046.
86. Campos SP, Baumann H Insulin is a prominent modulator of the cytokine-stimulated expression of acute-plasma protein genes. Mol Cel Biol 1992, 12:1789-1797.
87. O'Riordain MG, Ross JA, Fearon KC, Maingay J, Farouk M, Garden OJ, Carter DC Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol 1995, 269:E323-E330.
88. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
89. Wurfel MM, Hailman E, Wright SD Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995, 181:1743-1754.
90. Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab 2003, 88:1780-1784.
91. Harris HW, Grunfeld C, Feingold KR, Rapp JH Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990, 86:696-702.
92. Eggesbo JB, Lyberg T, Aspelin T, Hjermann I, Kierulf P Different binding of 125I-LPS to plasma proteins from persons with high or low HDL. Scand J Clin Lab Invest 1996, 56:533-543.
93. Jacob AI, Goldberg PK, Bloom N, Degenshein GA, Kozinn PJ Endotoxin and bacteria in portal blood. Gastroenterology 1977, 72:1268-1270.
94. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995, 155:3013-3020.
95. Summerfield JA, Sumiya M, Levin M, et al. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997, 314:1229-1232.
96. Best LG, Davidson M, North KE, et al. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation 2004, 109:471-475.
97. Megia A, Gallart L, Fernández-Real JM, et al. Mannosebinding lectin gene polymorphism are associated with gestational diabetes mellitus. J Clin Endocrinol Metab 2004, 89:5081-5087.
98. Joiner KA Complement evasion by bacteria and parasites. Annu Rev Microbiol 1988, 42:201-230.
99. Weyer C, Tataranni PA, Pratley RE Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000, 23:779-785.
100. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
101. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
102. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
103. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003, 88:3236-3240.
104. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42:231-234.
105. Fernández-Real JM, Castro A, Vázquez G, et al. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care 2004, 27:739-745.
106. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001, 108:1875-1881.
107. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-953.
108. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001, 98:2005-2010.
109. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin. Nat Med 2002, 8:731-737.
110. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
111. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. 2001 Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
112. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma Adiponectin Concentration Is Associated With Skeletal Muscle Insulin Receptor Tyrosine Phosphorylation, and Low Plasma Concentration Precedes a Decrease in Whole-Body Insulin Sensitivity in Humans. Diabetes 2002, 51:1884-1888.
113. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
114. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002, 99:16309-16313.
115. Kim J, Kim Y-J, Fillmore J, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001, 108:437-446.
116. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li Z-W, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkß. Science 2001, 293:1673-1677.
117. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002, 109:1321-1326.
118. Recasens M, López-Bermejo A, Ricart W, Vendrell J, Casamitjana R, Fernández-Real JM An inflammation score is better associated with basal than with stimulated indexes of insulin resistance. J Clin Endocrinol Metab 2005, 90:112-116.
119. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, Schlumberger W, Meyer J Impact of infectious burden on extent and longterm prognosis of atherosclerosis. Circulation 2002, 105:15-21.
120. Lev-Ran A Thrifty genotype:how applicable is it to obesity and type 2 diabetes?. Diabetes Rev 1999, 7:1-22.
121. Vozarova B, Fernández-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, et al. The interleukin-6 (-174) G/C promoter polymorphism is associated with type 2 diabetes mellitus in Native Americans and Caucasians. Human Genetics 2003, 112:409-413.